+
Site Tour

EuroPCR 2023: Improving outcomes in mitral regurgitation

Francesco Maisano, Marianna Adamo, Alison Duncan, Georg Nickenig and Greg Stone discuss the role of COAPT trial evidence in reducing mitral regurgitation and securing optimal outcomes for patients. Points also discussed include patient selection, repair or replacement, and real-world registry evidence on reducing MR with TEER.

Related Videos

EuroPCR 2023: COAPT 5-year follow-up

EuroPCR 2023: Defining the future

EuroPCR 2023: Vascular access

EuroPCR 2023: Tricuspid valve

TAVI Summit 2023: Aortic stenosis

EACTS 2021: Transcatheter mitral valve implantation

AV VALVES 2023: MR – Acute Rupture

T-TEER: echo procedural approach

Tendyne™: 6-Year Outcomes

Epic Mitral – 10-Year Clinical Outcomes

TAVI Summit - Cardiac imaging

TCT 21: EXPAND G4

TRENDING TOPICS

Epic Mitral – 10-Year Clinical Outcomes

Ten-Year Follow-Up of Mitral Valve Replacement With the Epic Porcine Valve

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Early outcomes on Epic Max platfrom

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline